(c) Regular inspections and checks are being carried out on the factories by the Competent Authorities to prevent the production and marketing of such spurious and unbranded Bidis, besides exploitation of labour.

Rectification of section against M/s. Carews Pharmaceuticals Ltd.

* 157. SHRI SANTOSH KUMAR SAHU:
SHRI N. E. BALARAM :

Will the PRIME MINISTER be pleased to refer to the answer to SQ No. 426 given in the Rajya Sabha on 6-8-92 and state :

(a) what action has been taken by Government to rectify the indiscriminatory action taken against M/s. Carews Pharmaceuticals Ltd; and

(b) what is the present status of action on the remaining two companies mentioned at Sr. No. (1) and (3) of the statement referred in the reply to SQ 4262 ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALE-IRO) : fa) and (b) No indiscriminatory action has been taken by the Government against M/s. Carews Pharmaceuticals India Limited. The present status of action taken on the two companies referred to at S. No. (1) and (3) of the Statement to the Starred Question No. 426 is as under :—

S. No	Name of Product and Company	Present Position of the Examination.
1.	Brustan (Stancare—a Division of M/s. Ranbexy)	The factual position whether the Company resubmitted price fixation application, with the required manufacturing licence from the FDA to BICP is to be ascertained.
2.	Anaflam (M/s. Vax Institute Laboratories Ltd. and marketed by M/s. Albert David)	The Company has not furnished the data on production/sales and prices charged from time to time, for the relevant period, so that the over-charged amount could be worked out. FDA West Bengal has also been requested to expedite the information from the company.